Gillies Hunter's Form 4 filing
Jade Biosciences, Inc. (JBIO) · filed Jan 19, 2024
- Accession no.
- 0001415889-24-001609
- Filed
- Jan 19, 2024
- Trade date
- Jan 17, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $78.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gillies HunterCIK 0001868997 | Officer (CHIEF MEDICAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 17, 2024 | Common Stock | MOption exerciseAcquired | +4,000 | $1.74 | +$6,960 | 7,251 | Direct | |
| Jan 17, 2024 | Common Stock | SSaleDisposed | −4,000 | $19.50 | −$78,000 | 3,251 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 17, 2024 | Common Stock | MOption exerciseDisposed | −4,000 | $0.00 | $0 | 6,027 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.